Relationship between long‐acting reversible contraception and acne in a cohort of adolescents and young adults

• Published in: Pediatric dermatology Vol. 41; no. 4; pp. 628 - 634
• Main Authors: Boos, Markus D., Ryan, Morgan E., Milliren, Carly, Golub, Sarah, Maslyanskaya, Sofya, Escovedo, Michelle, DiVasta, Amy, Pitts, Sarah
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.07.2024
• Subjects: Acne; Acne Vulgaris - drug therapy; Adolescent; Adolescents; Adult; Birth control; Contraception; Female; Humans; Incidence; Long-Acting Reversible Contraception - statistics & numerical data; Pediatrics; Population studies; Progestin; Prospective Studies; Quality control; Risk Factors; Severity of Illness Index; Statistical analysis; Teenagers; Young Adult; Young adults; adolescence; long‐acting reversible contraception; progestin; acne
• ISSN: 0736-8046; 1525-1470; 1525-1470
• DOI: 10.1111/pde.15578

The use of progestin-only long-acting reversible contraception (LARC) may be a risk factor for acne. Few studies have focused primarily on the effects of hormonal LARC on the development or exacerbation of acne in adolescents and young adults. We sought to understand the incidence and management of acne following hormonal LARC insertion in this adolescent/young adult population. A secondary data analysis was conducted of prospectively collected quality improvement (QI) data from the Adolescent Medicine LARC Collaborative. Subjects were evaluated by clinicians in adolescent medicine clinics at participating study sites, and acne severity was documented using a standardized recording instrument and scale. Descriptive statistics were reported as frequencies and percentages for categorical variables or mean and standard deviation (SD) for continuous variables. We compared demographic and clinical characteristics by those who had worsening acne, accounting for site inter-correlation using Cochran-Mantel-Haenszel chi-square tests for categorical variables and linear generalized estimating equation (GEE) regression for continuous variables. Of 1319 subjects who completed LARC insertion, 28.5% (376/1319) experienced worsening acne following use of progestin-only LARC. Acne was a contributing factor to LARC removal in only 3% (40/1319), and the sole reason for removal in 0.4% (5/1319) of all subjects. As this was a secondary analysis of prospectively collected QI data, limitations of this study include incomplete or inaccurate documentation of acne severity. Moreover, LARC insertions without follow-up/removal visits or with only follow-up/removal within 8 weeks of insertion were excluded from our study, which may also bias results. Adolescents and young adults seeking progestin-only LARC should be counseled about the potential for developing acne or experiencing a worsening of existing acne during LARC use. However, acne was not a common reason for LARC discontinuation.